Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02707900 · ClinicalTrials.gov registry record · Phase 1
Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02707900: Clinical Trial Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
NCT02707900 is a Phase 1 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02707900, a Phase 1 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this research study is to 1) evaluate the safety of a series of injections with the AGS-004 product in combination with a series of Vorinostat doses and 2) to help scientists evaluate ways of reactivating latent (non-acting) HIV virus and determine if the immune system can be made stronger to eliminate the activated HIV virus.
Primary Outcome
Change in the frequency of HIV infection per million resting CD4+T cells (RCI) from baseline to post-VOR/AGS.
Interventions
- DRUG Vorinostat
- BIOLOGICAL AGS-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-07-11 |
| Phase | Phase 1 |
Why NCT02707900 stopped before completion
NCT02707900 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT02707900 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02707900 about?
NCT02707900 is a clinical study titled "Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection". The purpose of this research study is to 1) evaluate the safety of a series of injections with the AGS-004 product in combination with a series of Vorinostat doses and 2) to help scientists evaluate ways of reactivating latent (non-acting) HIV virus and determine if the immune system can be made str...
What is the current status of trial NCT02707900?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-03. Estimated completion is 2018-07-11.
What interventions are being tested in trial NCT02707900?
The interventions under investigation include: Vorinostat (DRUG), AGS-004 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02707900?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02707900's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia